Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-023912
Filing Date
2022-11-09
Accepted
2022-11-09 16:26:03
Documents
47
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20220930.htm   iXBRL 10-Q 1496438
2 EX-10.1 evok-ex10_1.htm EX-10.1 37526
3 EX-31.1 evok-ex31_1.htm EX-31.1 17746
4 EX-31.2 evok-ex31_2.htm EX-31.2 18165
5 EX-32.1 evok-ex32_1.htm EX-32.1 12112
6 EX-32.2 evok-ex32_2.htm EX-32.2 13165
7 GRAPHIC img214338468_0.jpg GRAPHIC 233665
  Complete submission text file 0000950170-22-023912.txt   4997834

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT evok-20220930_def.xml EX-101.DEF 95425
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20220930_pre.xml EX-101.PRE 178386
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20220930_lab.xml EX-101.LAB 250719
11 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20220930.xsd EX-101.SCH 30998
12 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT evok-20220930_cal.xml EX-101.CAL 24174
41 EXTRACTED XBRL INSTANCE DOCUMENT evok-20220930_htm.xml XML 608542
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 221373065
SIC: 2834 Pharmaceutical Preparations